Category Archives: Clinical Cardiology

Is It A Heart Disease Or Digestive Disorders? Continue reading →

Diabetes, especially when uncontrolled, is strongly associated with progression to overt heart failure in patients with preclinical signs of heart failure, a new study shows. "Until now, studies of diabetes and heart failure have mainly been done in patients with overt heart failure Continue reading →

HEALTHTECH:Give me an overview of your career. How did you become interested in digital health Continue reading →

4D Molecular Therapeutics (NASDAQ:FDMT Get Rating) was upgraded by Zacks Investment Research from a sell rating to a hold rating in a research note issued to investors on Monday, Zacks.com reports. According to Zacks, 4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company which develops product candidates using its targeted and evolved adeno-associated viruses vectors. Continue reading →

WAYNE, Pa., June 07, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today has announced the launch of an Arrow Pressure Injectable Midline Catheter in Europe, the Middle East and Africa region. The addition of the pressure injectable catheter further enhances the Midline portfolio to meet the expanded needs of clinicians and is designed to improve patient safety Continue reading →

In general, the authors write, cardiovascular disorders fall into broad categories: Mendelian cardiovascular disorders, caused by the inheritance of just one or two genetic variants, and disorders with complex inheritance, with multiple genetic variants that are potentially contributing factors. In both categories, environmental and other non-genetic factors also contribute to the ultimate phenotypic expression, according to the document. However, Mendelian disorders often cluster in families, which may indicate an increased tilt toward family member screening in certain cases. Continue reading →

SAN FRANCISCO and SUZHOU, China, April 3, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announces that the results of a phase 3 clinical trial (Study code: CREDIT-2) of recombinant full-human anti-PCSK-9 monoclonal antibody (R&D code: IBI306, independently developed by Innovent) in Chinese patients with heterozygous familial hypercholesterolemia (HeFH) have been accepted as an abstract presented (E-poster #: 1188-005) at the American College of Cardiology Annual Congress 2022 (ACC 2022) Continue reading →

Complete revascularization improves angina-related quality of life in patients who have ST-segment elevation myocardial infarction (STEMI) with multivessel coronary artery disease, a new COMPLETE substudy shows. Continue reading →

New findings suggest patients taking renin-angiotensin-aldosterone system inhibitor (RAASi) medication for heart failure with reduced ejection fraction (HFrEF) had much lower blood potassium levels when taking patiromer, compared to placebo. As a result, patiromer may be used to control hyperkalemia, a side effect of RAASi therapy, in patients with HFrEF and help maintain normal serum potassium levels. These findings were presented at The American College of Cardiology (ACC) 2022 Scientific Sessions in Washington, DC Continue reading →

WASHINGTON, DCStructural valve deterioration is more common during midterm follow-up among patients with severe symptomatic aortic stenosis treated with a surgical bioprosthesis compared with those who receive the supra-annular, self-expanding transcatheter heart valve (Medtronic), according to a new analysis. The study, which combined data from multiple trials, showed that the rate of structural valve deterioration at 5 years with surgery was 4.38% versus 2.57% in patients undergoing TAVI (P = 0.0095). Michael Reardon, MD (Houston Methodist, TX), who presented the results today during the late-breaking clinical trial session at the American College of Cardiology (ACC) 2022 Scientific Session, said the results are important because they will help physicians in their conversations with patients Continue reading →